Nuclear medicine vendor ADAC Laboratories of Milpitas, CA, beganshipping its Molecular Coincidence Detection high-energy imagingupgrade this year, and reported that it had received 27 ordersfor MCD upgrades through the end of its fiscal year in
Nuclear medicine vendor ADAC Laboratories of Milpitas, CA, beganshipping its Molecular Coincidence Detection high-energy imagingupgrade this year, and reported that it had received 27 ordersfor MCD upgrades through the end of its fiscal year in September.ADAC plans to show improvements in reconstruction algorithms forMCD at its RSNA booth, according to Jeff Nelson, vice presidentof marketing.
Also look for ADAC to present final results of its multicenterclinical trial for Vantage, an attenuation-correction feature.The results indicate that Vantage can help reduce false positivesin nuclear cardiology studies, Nelson said. ADAC has developeda second-generation version of Vantage that incorporates scattercorrection and gated SPECT.
Vertex Plus is the third generation of ADAC's variable-angledual-head gamma camera, and features improvements to the system'sergonomics and patient handling, according to Nelson.
The most interesting news at ADAC's booth, however, isn't relatedto a new product, but rather an acquisition with intriguing ramifications:sources indicate the vendor will annouce the purchase of managedservice organization Medical Transition Strategies of Atlanta,the parent of Georgia Radiology Network.
ADAC is expected to form a new business unit to encompass itswork in developing physician networks that can contract with payorslike managed-care organizations. ADAC could use Georgia RadiologyNetwork as a model in setting up radiology networks in other states.The company declined to comment officially on the acquisitionprior to the RSNA show.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.